Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study

被引：0
|
作者：
C Hanotin
F Thomas
SP Jones
E Leutenegger
P Drouin
机构：
[1] Laboratoires Knoll France,Department of Clinical Research
[2] Knoll Pharmaceuticals,Department of Clinical Research
[3] Service de Diabétologie,undefined
[4] Maladies Métaboliques et Nutrition,undefined
[5] CHU de Nancy,undefined
[6] Hôpital Jeanne d'Arc,undefined
来源：
International Journal of Obesity | 1998年 / 22卷
关键词：
obesity; weight loss; sibutramine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
OBJECTIVES: To assess the weight-reducing effects and tolerability of 5 mg, 10 mg and 15 mg daily doses of sibutramine, a novel serotonin and noradrenaline reuptake inhibitor (SNRI).
引用
收藏
页码：32 / 38
页数：6
相关论文
共 50 条
  • [1] Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study
    Hanotin, C
    Thomas, F
    Jones, SP
    Leutenegger, E
    Drouin, P
    INTERNATIONAL JOURNAL OF OBESITY, 1998, 22 (01) : 32 - 38
  • [2] SIBUTRAMINE DOSE-RANGING, EFFICACY STUDY IN OBESITY
    WEINTRAUB, M
    RUBIO, A
    GOLIK, A
    BYRNE, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (02) : 172 - 172
  • [3] SIBUTRAMINE IN WEIGHT CONTROL - A DOSE-RANGING, EFFICACY STUDY
    WEINTRAUB, M
    RUBIO, A
    GOLIK, A
    BYRNE, L
    SCHEINBAUM, ML
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (03) : 330 - 337
  • [4] A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients
    Chang, TT
    Gish, RG
    Hadziyannis, SJ
    Cianciara, J
    Rizzetto, M
    Schiff, ER
    Pastore, G
    Bacon, BR
    Poynard, T
    Joshi, S
    Klesczewski, KS
    Thiry, A
    Rose, RE
    Colonno, RJ
    Hindes, RG
    GASTROENTEROLOGY, 2005, 129 (04) : 1198 - 1209
  • [5] Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study
    Van Gaal, LF
    Broom, JI
    Enzi, G
    Toplak, H
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (02) : 125 - 132
  • [6] Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study
    L. F. Van Gaal
    J. I. Broom
    G. Enzi
    H. Toplak
    European Journal of Clinical Pharmacology, 1998, 54 : 125 - 132
  • [7] Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study
    Rentzhog, L
    Stanton, SL
    Cardozo, L
    Nelson, E
    Fall, M
    Abrams, P
    BRITISH JOURNAL OF UROLOGY, 1998, 81 (01): : 42 - 48
  • [8] DOSE-RANGING STUDY TO DETERMINE THE TOLERABILITY OF TIAGABINE HCL ADMINISTERED AS MONOTHERAPY
    SCHACHTER, S
    WANNAMAKER, B
    CAHILL, W
    SACHDEO, R
    HEARELL, K
    SHU, V
    HIGHTOWER, B
    SOMMERVILLE, K
    EPILEPSIA, 1995, 36 : S148 - S148
  • [9] A dose-ranging study of rapacuronium in pediatric patients
    Meakin, GH
    Meretoja, OA
    Motsch, J
    Taivainen, T
    Wirtavuori, K
    Schönstedt, R
    Perkins, R
    McCluskey, A
    ANESTHESIOLOGY, 2000, 92 (04) : 1002 - 1009
  • [10] STUDY DESIGNS FOR DOSE-RANGING
    SHEINER, LB
    BEAL, SL
    SAMBOL, NC
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (01) : 63 - 77
12345